Frank Dörje

2.4k total citations · 1 hit paper
49 papers, 1.5k citations indexed

About

Frank Dörje is a scholar working on Pediatrics, Perinatology and Child Health, Geriatrics and Gerontology and Epidemiology. According to data from OpenAlex, Frank Dörje has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pediatrics, Perinatology and Child Health, 18 papers in Geriatrics and Gerontology and 9 papers in Epidemiology. Recurrent topics in Frank Dörje's work include Pharmaceutical Practices and Patient Outcomes (18 papers), Pharmaceutical studies and practices (18 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Frank Dörje is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (18 papers), Pharmaceutical studies and practices (18 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Frank Dörje collaborates with scholars based in Germany, United States and Switzerland. Frank Dörje's co-authors include Mark R. Brann, J. Wess, E. Mutschler, G. Lambrecht, Reinhold Tacke, Allan I. Levey, Martin F. Fromm, T I Bonner, Jörg König and N Wolf and has published in prestigious journals such as Gastroenterology, Journal of Pharmacology and Experimental Therapeutics and British Journal of Pharmacology.

In The Last Decade

Frank Dörje

42 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antagonist binding profiles of five cloned human muscarinic receptor subtypes.

1990 549 citations Frank Dörje et al. profile →

Peers

Countries citing papers authored by Frank Dörje

Since Specialization

Citations

This map shows the geographic impact of Frank Dörje's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Dörje with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Dörje more than expected).

Fields of papers citing papers by Frank Dörje

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Dörje. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Dörje. The network helps show where Frank Dörje may publish in the future.

Co-authorship network of co-authors of Frank Dörje

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Dörje. A scholar is included among the top collaborators of Frank Dörje based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Dörje. Frank Dörje is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Continuity of medication information transfer and continuous medication supply during hospital-to-home transitions - nationwide surveys in hospital and community pharmacies after implementing new legal requirements in Germany 2024 ·BMC Health Services Research ·(unknown), Frank Dörje, (unknown), (unknown), (unknown), Hanna M. Seidling	0
2	Interprofessional Evaluation of a Medication Clinical Decision Support System Prior to Implementation 2024 ·Applied Clinical Informatics ·(unknown), (unknown), (unknown), (unknown), Martin F. Fromm, Frank Dörje	2
3	A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center 2024 ·JCO Oncology Practice ·(unknown), (unknown), (unknown), (unknown), Rainer Fietkau, Jürgen Siebler, Marianne Pavel, Markus F. Neurath, Carola Berking, Bernd Wullich, (unknown), Matthias W. Beckmann, Martin F. Fromm, Frank Dörje	1
4	Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study 2024 ·Therapeutic Advances in Gastroenterology ·Sarah Fischer, (unknown), (unknown), (unknown), Marcel Vetter, (unknown), Peter Dietrich, Timo Räth, (unknown), (unknown), Sabine Krebs, Frank Dörje, Daniel Nagore, Sebastian Meyer, Markus F. Neurath, Raja Atreya	1
5	Possible manufacture of test allergens in public pharmacies for the diagnosis of type I allergies: Legal aspects 2024 ·PubMed ·(unknown), Sabine Kespohl, (unknown), (unknown), Andreas Bonertz, Ingrid Sander, (unknown), (unknown), (unknown), Ralph Heimke-Brinck, Frank Dörje, (unknown), Matthias Meyer, (unknown), (unknown), (unknown), Stefan Schülke, Monika Raulf, Vera Mahler	0
6	From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Frank Dörje, Martin F. Fromm, (unknown)	0
7	Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial 2024 ·Inflammatory Bowel Diseases ·(unknown), (unknown), Tobias Hepp, Peter Dietrich, Sarah Fischer, Sabine Krebs, Markus F. Neurath, Frank Dörje, Raja Atreya	2
8	New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial 2022 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), (unknown), Norbert Meidenbauer, Frank Kunath, Peter J. Goebell, Andréas Mackensen, Frank Dörje, Martin F. Fromm, Bernd Wullich	5
9	Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab 2021 ·Therapeutic Advances in Gastroenterology ·Sarah Fischer, (unknown), (unknown), H Schmitt, Francesco Vitali, Simon Hirschmann, Andreas Ramming, Sebastian Zundler, Timo Räth, Sabine Krebs, Frank Dörje, Wolfgang Uter, Daniel Nagore, Sebastian Meyer, Markus F. Neurath, Raja Atreya	19
10	NP-002 Medication safety in patients treated with oral antitumor agents: a prospective, randomised investigation to improve patient safety and well-being by intensified clinical pharmaceutical/pharmacological care 2020 ·(unknown), (unknown), Martin F. Fromm, Frank Dörje	0
11	Apotheker auf der Palliativstation: Auswirkung auf Arzneimitteltherapie und Therapiekosten 2019 ·Der Schmerz ·(unknown), Frank Dörje, Carsten Klein, Christoph Ostgathe	3
12	Clinical pharmacy services in Germany: a national survey 2019 ·European Journal of Hospital Pharmacy ·Cláudia Schulz, Andreas Fischer, (unknown), (unknown), (unknown), (unknown), (unknown), Claudia Langebrake, Torsten Hoppe‐Tichy, Frank Dörje, Holger Knoth	21
13	Advances in clinical pharmacy education in Germany: a quasi-experimental single-blinded study to evaluate a patient-centred clinical pharmacy course in psychiatry 2017 ·BMC Medical Education ·(unknown), Andreas Mayr, (unknown), Johannes Kornhuber, Frank Dörje, Kristina Friedland	10
14	Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project 2014 ·Oncology ·Axel Wein, Martin Emmert, Susanne Merkel, (unknown), Juergen Siebler, (unknown), Christof Lamberti, (unknown), (unknown), Alexander Kiani, Rudolf Schlag, M. Grüner, Simone Steinbild, (unknown), (unknown), Frank Dörje, Thomas Horbach, Oliver Schöffski, Markus F. Neurath, Werner Hohenberger	8
15	Intensified pharmaceutical care is improving immunosuppressive medication adherence in kidney transplant recipients during the first post-transplant year: a quasi-experimental study 2014 ·Nephrology Dialysis Transplantation ·(unknown), Frank Dörje, Judith Schwitulla, Kai‐Uwe Eckardt, Christian Hugo	56
16	S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der GESKES und der AKE 2013 ·Aktuelle Ernährungsmedizin ·S. Bischoff, Jann Arends, Frank Dörje, Peter Engeser, (unknown), (unknown), Andreas Leischker, Stefan Mühlebach, (unknown), (unknown), (unknown), (unknown), Zeno Stanga, (unknown)	14
17	Palliative treatment of colorectal cancer in Germany: cost of care and quality of life 2012 ·The European Journal of Health Economics ·Martin Emmert, (unknown), Axel Wein, Frank Dörje, Susanne Merkel, Frank Boxberger, (unknown), (unknown), (unknown), (unknown), Christof Lamberti, Markus F. Neurath, Werner Hohenberger, Oliver Schöffski	14
18	Hospital use of systemic antifungal drugs 2005 ·PubMed ·Katja de With, Michaela Steib–Bauert, Holger Knoth, Frank Dörje, (unknown), Ulrich Rothe, Ludwig Maier, Winfried V. Kern	37
19	Antibiotic use in German university hospitals 1998–2000 (Project INTERUNI-II) 2004 ·International Journal of Antimicrobial Agents ·Katja de With, (unknown), (unknown), Frank Dörje, (unknown), Manfred Haber, Michael Hartmann, Ulrich Rothe, (unknown), Michaela Steib–Bauert, Winfried V. Kern	32
20	Antibiotikaanwendung an deutschen Hochschulkliniken (Projekt INTERUNI-II) 2004 ·Medizinische Klinik ·(unknown), (unknown), (unknown), Frank Dörje, (unknown), Manfred Haber, Michael Hartmann, Ulrich Rothe, (unknown), Michaela Steib–Bauert, Winfried V. Kern	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact